Get Report in 5 to 7 Working Days
Global Gout Therapeutics Market: Overview
Gout is a physical conditions that affects the patient’s ability to move, often also termed as unwalkable disease, and it has been around for centuries. But in the recent times, especially in the U.S., the prevalence of gout has increased to greater extents, which is a reflection of growing population with obesity, smoking habits, and increased intake of alcohol. Increased level of uric acid in the body and uncontrolled metabolic disorders are some of the common symptoms of gout.
There are a number of therapies available for the treatment of gout, which also helps in preventing future flares and reduce the risk of kidney stone. These therapies help in reducing the uric acid levels in the body as well as enhance kidney’s ability to discard uric acid via urine. Consequently, the demand in the global gout therapeutics market is expected to increment at a healthy CAGR during the forecast period of 2017 to 2025.
Global Gout Therapeutics Market: Key Trends
Increased research and development in the field has yielded significantly more effective medications in the recent times, which are recommended to patients on the basis of severity of the condition. Introduction of urate-lowering agents is one of the primary driver of the gout therapeutics market. First line therapies such as Febuxostat and Allopurinol are now replaced urate-lowering agents such as Lesinurad, which help in reducing pain as well as negotiate the risk of joint destruction. The growing popularity of OTC drugs such as Oral colchicine, corticosteroids, and NASAIDs, which are quite effective in moderate gout indications, are also favoring the global gout therapeutics market in the positive direction. Technological advancements in medical imaging is another factor augmenting the demand in the gout therapeutics market. On the other hand, low levels of physician and patient awareness, heavy dependency on generic drugs, and use of CAM for the treatment of gout are restraining factors over the global gout therapeutics market.
Global Gout Therapeutics Market: Market Potential
Focus on regenerative medicines, high growth potential of biologics, and preference of combination therapies such as are some of the trends that bode well for the future of gout therapeutics market. Biologics such as Canakinumab, Rilonacept, and Krystexxa have been proven to efficiently address gout-related conditions. Combination therapies such as allopurinol and benzbromarone are able to treat gout by reducing the renal dyfunction.
Global Gout Therapeutics Market: Regional Outlook
Currently, North America serves the maximum demand in the global gout therapeutics market, owing to the presence of several prominent players in the U.S., high cost of branded therapies in the U.S., and growing use of gout therapy. Throughout the forecast period, North America is expected to remain the most lucrative market, also gaining traction from impending launch of several urate-lowering agents. On the other hand, vastly populated Asia Pacific is another lucrative region for the vendors venturing in this market. This region not only has a large pool of patients, improving healthcare infrastructure in emerging economies such as India, Japan, and Malaysia as well as changing lifestyle with smoking- and alcohol-related diseases will further escalate the demand in the gout treatment market.
Global Gout Therapeutics Market: Competitive Landscape
Horizon Pharma, AstraZeneca, and Takeda Pharmaceuticals are identified as the most prominent companies in moderately consolidated market for gout therapeutics. These companies lead via research and development and have a profile of drugs with high efficacy.
Novartis, Eli Lilly, Alder Biopharmaceuticals, Can-Fite BioPharma, Celgene, Ablynx, Lexicon Pharmaceuticals, Merck, Boehringer Ingelheim, Celltrion, CymaBay Therapeutics, GlaxoSmithKline, ChemoCentryx, Gilead Sciences, Ironwood Pharmaceuticals, Incyte, KaloBios Pharmaceuticals, Morphotek, Sanofi, Santarus, and Selecta Biosciences are some of the other key companies in the global gout therapeutics market.
The study presents reliable qualitative and quantitative insights into:
The regional analysis covers:
The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.
Highlights of the report:
Note: Immense care has been taken to present data with the highest levels of accuracy in all TMRResearch reports. Nevertheless, recent developments related to market/vendor landscape may take time to reflect in the analysis.
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report